Hypertension in continuous ambulatory peritoneal dialysis patients: What do we know and what can we do about it?

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Cheigh, Jhoong S ^a,c   Kim, Hyang ^b  

^a ROGOSIN INSTITUTE   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INCIDENCE; MORTALITY; PRIORITY JOURNAL; UNITED STATES;

EID: 0033402028     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s22     Document Type: Conference Paper

References (37)

1. United States Department of Health and Human Services, Public Health Service, National Institutes of Health. USRDS 1998 Annual Data Report. Bethesda, MD: United States Renal Data System; 1998.
2. Lameire N, Bernaert P, Lambert MC, Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 1994; 46(Suppl 48):S31-8.
3. Department of Health and Human Services. 1997 Annual Report. ESRD Core Indicators Project. December 1997.
4. Department of Health and Human Services. 1996 Annual Report. ESRD Core Indicators Project. January 1997.
5. Saldanha L, Weiler EWJ, Gonick HC. Effect of continuous ambulatory peritoneal dialysis on blood pressure control. Am J Kidney Dis. 1993; 21:184-8.
6. Cheigh JS. The role of ambulatory blood pressure monitoring in patients with end-stage renal disease. Semin Dial. 1998; 11:148-50.
7. Rodby RA, Vonesh EF, Korbet SM. Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring. Am J Kidney Dis. 1994; 23:401-11.
8. Canziani ME, Neto MC, Saragoca MA, Cassiolato JL, Ramos OL, Ajzen H, et al. Hemodialysis versus continuous ambulatory peritoneal dialysis: Effects on the heart. Artif Organs. 1995; 19:241-4.
9. Cheigh JS, Serur D, Paguirigan M, Stenzel KH, Rubin A. How well is hypertension controlled in CAPD patients? In: Khanna R, ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1994; 10:55-9.
10. Enia, G. Impact of hypertension in CAPD patients. Contrib Nephrol. 1996; 119:147-51.
11. Zazgornik J, Biesenbach G, Forstenlahner M, Stummvoll K. Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy. Clin Nephrol. 1997; 48:337-40.
12. Tomita J, Kimura G, Inoue T, Inenaga T, Sanai T, Kawano Y, et al. Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis. 1995; 25:405-12.
13. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, et al. Survival as an index of adequacy of dialysis. Kidney Int. 1992; 41:1286-91.
14. United States Renal Data System. USRDS 1992 Annual Report: VI. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis. 1992; 2:32-8.
15. Lowrie EG, Huang NL, Lew NL, Liu Y. The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA, ed. Death on Dialysis: Preventable or Inevitable? Dordrecht: Kluwer Academic Publishers; 1994:121-41.
16. Duranti E, Imperiali P, Sasdelli M. Is hypertension a mortality risk factor in dialysis? Kidney Int. 1996; 49:173-4.
17. Foley RN, Parfrey P, Harnett J, Kent G, Murray D, Barré P. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996; 49:1379-85.
18. Zager PG, Nikolic J, Brown R, Campbell M, Hunt W, Peterson D, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998; 54:561-9.
19. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso G. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. 1993; 44:881-6.
20. National Institutes of Health. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1997; 157:2413-46.
21. Hansson L, Zanchetti A, Carruthers G, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62.
22. Manolio T, Cutler J, Furbeg C, Psaty B, Whelton P, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155:829-37.
23. Psaty B, Smith N, Siscovick D, Koepsell T, Weiss N, Heckbert S, et al. Health outcomes associated with antihypertensive therapies used as first line agents. JAMA. 1997; 277:739-45.
24. Alderman M, Cohen H, Roque R, Madhaven S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997; 349:594-8.
25. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction trial and other recent studies. Am J Cardiol. 1991; 67: 1295-7.
26. Psaty BM, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5.
27. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92:1326-31.
28. Estacio R, Jeffers B, Hiatt W, Biggerstaff S, Gifford N, Schrier R. The effect of Nisoldipine as compared with Enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-82.
29. Wong KC, Woo KS, Lam WK, Li KT, Lai KN, Nicholls MG, et al. A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients. Int J Artif Organs. 1995; 18:757-62.
30. Favazza A, Montanaro D, Messa P, Antonucci F, Gropuzzo M, Mioni G. Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril and nifedipine. Perit Dial Int. 1992; 12:287-91.
31. Semple PF. Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J. 1988; 296:86-8.
32. Pedro P, Gehr TWB, Sica D, Fakhry I, Farthing D. The pharmacokinetics and pharmacodynamics of Losartan in CAPD patients [Abstract]. Perit Dial Int. 1998; 18(Suppl 1):S53.
33. Burt VL, Whelton P, Rocella EJ. Prevalence of hypertension in the U.S. adult population. Results from the Third National Health and Nutrition Examination Study. Hypertension. 1995; 25:305-13.
34. Burt VL, Cutler JA, Higgins M. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the Health Examination Studies, 1960 to 1961. Hypertension. 1995; 26:60-9.
35. Velasquez MT, Lew SQ, Albertini V, Mishkin G, Bosch J. Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients. Clin Nephrol. 1997; 48:341-5.
36. Cheigh JS, Milite C, Sullivan J, Rubin A, Stenzel K. Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis. 1992; 19:453-9.
37. Nakayama M, Kawaguchi Y, Yokoyama K, Kubo H, Miura Y, Watanabe S, et al. Antihypertensive effect of low Na concentration (120 mEq/L) solution for CAPD patients. Clin Nephrol. 1994; 41:357-63.